Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced Dose Chemotherapy + Pembrolizumab in Vulnerable/Older Adults with Advanced NSCLC
NCT06731413Phase 2Recruiting
- Sponsor
- Virginia Commonwealth University
- Start
- Feb 2025
- Primary completion
- Jul 2030
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, carboplatin, Paclitaxel Micelles for Injection, pemetrexed in non-small cell lung cancer (NSCLC), sponsored by Virginia Commonwealth University. Started Feb 2025; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06731413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06731413.